LAUSR

Agarwal, R., Chan, Y.C., Tam, C.S., Hunter, T., Vassiliadis, D., Teh, C.E., Thijssen, R., Yeh, P., Wong, S.Q., Ftouni, S., Lam, E.Y.N., Anderson, M.A., Pott, C., Gilan, O., Bell, C.C., Knezevic, K., Blombery, P., Rayeroux, K., Zordan, A., Li, J., Huang, D.C.S., Wall, M., Seymour, J.F., Gray, D.H.D., Roberts, A.W., Dawson, M.A. & Dawson, S.J. (2019) Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nature Medicine, 25, 119–129. Blombery, P., Anderson, M.A., Gong, J.N., Thijssen, R., Birkinshaw, R.W., Thompson, E.R., Teh, C.E., Nguyen, T., Xu, Z., Flensburg, C., Lew, T.E., Majewski, I.J., Gray, D.H.D., Westerman, D.A., Tam, C.S., Seymour, J.F., Czabotar, P.E., Huang, D.C.S. & Roberts, A.W. (2019) Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discovery, 9, 342–353. Correia, C., Schneider, P.A., Dai, H., Dogan, A., Maurer, M.J., Church, A.K., Novak, A.J., Feldman, A.L., Wu, X., Ding, H., Meng, X.W., Cerhan, J.R., Slager, S.L., Macon, W.R., Habermann, T.M., Karp, J.E., Gore, S.D., Kay, N.E., Jelinek, D.F., Witzig, T.E., Nowakowski, G.S. & Kaufmann, S.H. (2015) BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood, 125, 658–667. Davids, M.S., Roberts, A.W., Seymour, J.F., Pagel, J.M., Kahl, B.S., Wierda, W.G., Puvvada, S., Kipps, T.J., Anderson, M.A., Salem, A.H., Dunbar, M., Zhu, M., Peale, F., Ross, J.A., Gressick, L., Desai, M., Kim, S.Y., Verdugo, M., Humerickhouse, R.A., Gordon, G.B. & Gerecitano, J.F. (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. Journal of Clinical Oncology, 35, 826–833. Fresquet, V., Rieger, M., Carolis, C., Garcia-Barchino, M.J. & Martinez-Climent, J.A. (2014) Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT199 in lymphoma. Blood, 123, 4111–4119. Jayappa, K.D., Portell, C.A., Gordon, V.L., Capaldo, B.J., Bekiranov, S., Axelrod, M.J., Brett, L.K., Wulfkuhle, J.D., Gallagher, R.I., Petricoin, E.F., Bender, T.P., Williams, M.E. & Weber, M.J. (2017) Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv, 1, 933–946. Moreau, P., Chanan-Khan, A., Roberts, A.W., Agarwal, A.B., Facon, T., Kumar, S., Touzeau, C., Punnoose, E.A., Cordero, J., Munasinghe, W., Jia, J., Salem, A.H., Freise, K.J., Leverson, J.D., Enschede, S.H., Ross, J.A., Maciag, P.C., Verdugo, M. & Harrison, S.J. (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood, 130, 2392–2400. Punnoose, E.A., Leverson, J.D., Peale, F., Boghaert, E.R., Belmont, L.D., Tan, N., Young, A., Mitten, M., Ingalla, E., Darbonne, W.C., Oleksijew, A., Tapang, P., Yue, P., Oeh, J., Lee, L., Maiga, S., Fairbrother, W.J., Amiot, M., Souers, A.J. & Sampath, D. (2016) Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Molecular Cancer Therapeutics, 15, 1132–1144. Roberts, A.W., Davids, M.S., Pagel, J.M., Kahl, B.S., Puvvada, S.D., Gerecitano, J.F., Kipps, T.J., Anderson, M.A., Brown, J.R., Gressick, L., Wong, S., Dunbar, M., Zhu, M., Desai, M.B., Cerri, E., Heitner Enschede, S., Humerickhouse, R.A., Wierda, W.G. & Seymour, J.F. (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374, 311–322. Seymour, J.F., Ma, S., Brander, D.M., Choi, M.Y., Barrientos, J., Davids, M.S., Anderson, M.A., Beaven, A.W., Rosen, S.T., Tam, C.S., Prine, B., Agarwal, S.K., Munasinghe, W., Zhu, M., Lash, L.L., Desai, M., Cerri, E., Verdugo, M., Kim, S.Y., Humerickhouse, R.A., Gordon, G.B., Kipps, T.J. & Roberts, A.W. (2017) Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. The lancet Oncology, 18, 230–240.